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Tumor therapy using cytokines has been developed for last 
two decades. Several recombinant cytokines and tumor cell 
vaccines produced by cytokine gene transfer have been in 
clinical trials, but several side effects hamper routine clinical 
applications. Many cytokines are originally expressed as 
membrane-bound form and then processed to secretory 
form exerting paracrine effects. Though functional differ-
ences of these two types of cytokines are elusive yet, the 
membrane-bound form of cytokine may exert its effects on 
restricted target cells as a juxtacrine, which are in physical 
contacts. With the efforts to improve antitumor activities of 
cytokines in cancer patients, developing new strategies to al-
leviate life-threatening side effects became an inevitable 
goal of tumor immunologists. Among these, tumor cell vac-
cines expressing cytokines as membrane-bound form on tu-
mor cell surface have been developed by genetic engineering 
techniques with the hope of selective stimulation of the tar-
get cells that are in cell-to-cell contacts. In this review, recent 
progress of tumor cell vaccines expressing membrane-bound 
form of cytokines will be discussed.
[Immune Network 2009;9(5):158-168]
INTRODUCTION
The eventual goal of tumor immunologists is to enhance sys-
temic immunity against tumor cells. Cytokines are attractive 
agents  to  modulate  immune  responses  in  disease  states  in-
cluding cancer. Since the demonstration that endotoxin treat-
ment induced rejection of established cancer, findings of in-
terleukin-1  and  interferon  were  followed  as  effective  tumor 
killing  molecules,  and  recombinant  cytokine  therapy  began 
to  draw  attention  with  much  enthusiasm.  For  example,  re-
combinant IL-2, IL-12, GM-CSF got major focus in initial trials 
of  tumor  therapy.  However,  on  the  contrary  to  the  initial 
hope, various unpredicted side effects of recombinant cyto-
kines hampered clinical applications. Later by development 
of new technology of gene transfer and gene delivery system, 
cytokine gene transfer methods became an alternative way to 
deliver cytokines in restricted region. The enormous evalua-
tion of available cytokines by gene transfer into autologous 
tumors of various origins have been reported (1). Tumor cells 
transduced with cytokine genes sometimes became immuno-
genic,  regressed  spontaneously  in  vivo,  and  eventually  in-
duced  antitumor  immunity  (2-4).
    G e n e r a l l y  s p e a k i n g ,  t u m o r  b e a r e r s  a r e  s o m e h o w  i m -
munocompromised in functions of T cells (5). Malfunction of 
immune system in tumor bearers is also implicated with dis-
abled dendritic cells (DCs) (6). Supplementation of the cyto-
kines defected in tumor patients could be one of way to re-
verse the overwhelmed status by tumor growth. The hypoth-
esis became the ground of cytokine gene transfer into tumor 
cells as a tumor cell vaccine. However, the expression of cy-
tokines by tumor cells also showed various side effects when 
the tumor cell vaccines were injected  in vivo. Furthermore, 
the  infiltrated  immune  cells  into  the  regressing  tumor  mass 
were  mainly  non-specific  to  the  tumor.  These  indicate  that 
the  local  cytokine  release  also  activates  bystander  immune 
cells and causes various cytokine productions from them. The 
local cytokine cocktail may cause the unexpected side effects 
in cytokine gene transfer methods. One of way to avoid the 
bystander  cell  activation  would  be  to  confine  the  effective 
range of cytokine expressed by tumor cell vaccine. By ex-
pressing  cytokine  on  tumor  cell  surface  as  a  membrane- 
bound form (mbCytokine), selective activation of target cells Membrane-bound Form of Cytokine
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Table I. Targeted effector cells by tumor vaccines expressing membrane-bound form of cytokines
Mode of expression Cytokines Targeted effectors References
Secretory and memebrane-bound
Secretory only
TNFα
M-CSF
Flt3-ligand
Fractalkine
IL-2
IL-4
IL-12
GM-CSF
IFN-γ
T cells
Monocytes, macrophages
DC
NK, T cells
T cells, CTL
CTL
Th1, NK, B cells
DC, macrophages
NK, T cells
(26,27)
(36)
(86-88)
(92, 94)
(55-59)
(65,66)
(55,65,82,83)
(32-35)
(34)
could be achieved (see Table I). As a natural form, several 
cytokines including IL-1 (7), IL-15 (8), M-CSF (9), Flt3-eigand 
(10), TNFα (11), LTα (12), fractalkine (13), TGFβ (14), and 
IFN-γ (15), are expressed as membrane-associated form as 
well  as  sescretory  form.  The  functional  distinction  between 
the  membrane-bound  form  and  the  secretory  form  has  not 
been clarified yet in most of cytokines. Superficially, the ef-
fective range of the membrane-bound form may be confined 
to the cells that are in physical contacts, but secretory form 
would  have  wider  effective  range.
TUMOR THERAPY USING MEMBRANE-BOUND FORM 
OF TNFα
Tumor  necrosis  factor  a  (TNFα)  was  discovered  in  1975 
through the anticancer activity of sera from mice injected with 
endotoxin (16). TNFα is produced by various cell types in-
cluding macrophages, T lymphocytes, endothelial cells, and 
K u p f f e r  c e l l s .  T w o  b i o a c t i v e  f o r m s  a r e  k n o w n ;  a  2 6  k D a  
transmembrane form, and a 17 kDa secrtory form (11). The 
26  kDa  protein  expressed  as  a  membrane-bound  from 
(mbTNFα) is cleaved into 17 kDa secretory form by mem-
brane-bound  metalloproteases,  including  TNFα  converting 
enzyme (ADAM17/TACE/CD156q) (17,18). The mbTNFα can 
kill various types of tumor cells which are resistant to secre-
tory TNFα (19), participates in the interaction between acti-
vated T and B lymphocytes (20), and enhances macrophage 
responses  towards  Leishmania ( 2 1 ) ,  w h e r e a s  t h e  s e c r e t o r y  
form is mainly responsible for endotoxic shock (22). TNFα 
is able to kill many kinds of tumor cells in vivo as well as 
in vitro. The clinical applications of the soluble trimeric form 
of TNFα have been hampered because therapeutic doses of 
this potent cytokine have been accompanied by serious sys-
temic  toxic  side  effects,  such  as  septic  shock  and  cachexia 
(23,24). To alleviate these life-threatening side effects, and to 
improve the antitumor activities of TNFα, Graham and col-
leagues  generated  adenovirus  vectors  expressing  mbTNFα 
(25). The toxicity of TNFα was much reduced by local ex-
pression and prevention from circulatory system. Wild type 
TNFα expressing vector was highly  toxic, whereas the ad-
enovirus  vector  expressing  a  mutant  non-secreted  (mem-
brane-bound)  form  showed  low  toxicity  at  the  same  dose. 
Both vectors induced permanent tumor regressions in some 
cases, and the cured mice displayed protective immunity and 
specific CTL activity against the original tumor. These results 
indicate that the adenovirus vector expressing mbTNFα can 
reduce  systemic  toxicity  without  compromising  antitumor 
activity.
    In  comparison  of  mbTNFα a nd  se cr et o ry  TN Fα in  an t i-
tumor effects, Li and colleagues generated three different re-
combinant retroviral vectors encoding wild-type TNFα, secre-
table TNFα mutant, and uncleavable transmembrane TNFα 
mutant (26). They identified a transient weight loss in mice 
bearing  solely  secretable  TNFα mutant  producing  tumor, 
whereas no obvious side effects were seen in mice bearing 
uncleavable  TNFα m u t a n t  o r  w i l d  t y p e  T N F α expressing 
tumors. Moreover, the tumors expressing soluble TNFα pro-
moted  the  subsequent  infiltration  of  CD4＋ T  cells,  and  to 
a lesser extent CD8＋ T cells to the tumor sites. The mbTNF
α expressing  tumors  up-regulated  Fas  (CD95)  expression 
and inhibited the expression of tumor metastasis associated 
CD44v3, suggesting the difference of secretory TNFα from 
mbTNFα in killing tumor cells in vivo. Recently, it was found 
that the TNFα mutation on ADAM-17 cleavage site was not 
enough to prevent cleavage and secretion of TNFα. To avoid 
the  effect  of  secretory  TNFα effect  completely,  Kipps  and 
colleagues expressed a chimeric protein with extracellular do-
main of TNFα and transmembrane stalk portion of CD154 Membrane-bound Form of Cytokine
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using adenovirus vector system and tested its antitumor activ-
ity  (27).  The  systemic  toxicity  was  not  seen  with  the  ad-
enovirus  vector  expressing  TNFα-CD154  chimera.  The 
WEHI-164 fibrosarcoma tumor was regressed by the injection 
of  the  TNFα-CD154  expressing  vector  intratumorally,  and 
survival of mice was much extended compared with the mice 
i n j e c t e d  w i t h  t h e  v e c t o r  e x p r e s s i n g  w i l d  t y p e  o f  T N F α. 
Analysis on the effector cells involved in the antitumor activity 
by  mbTNFα producing  tumor  cell  vaccine  would  provide 
more  information  on  the  functional  differentiation  from  the 
secretory  form.
TUMOR THERAPY USING MEMBRANE-BOUND 
FORM OF GM-CSF
G M - C S F  i s  e x p r e s s e d  a s  a  2 3 ∼29  kDa  glycoprotein  by  a 
number of different cell types (28,29), and has stimulatory ef-
fect on the proliferation and maturation of myeloid progenitor 
cells  in  vitro.  GM-CSF  also  plays  a  critical  role  in  differ-
entiation  and  proliferation  of  DCs  from  hematopoietic  pre-
cursor cells (30). It was one of the first hematopoietic regu-
lators  clinically  applied  along w i t h  G - C S F ,  f o r  e x a m p l e ,  t o  
ameliorate  chemotherapy-induced  neutropenia  and  to  help 
hematopoietic  reconstitution  after  bone-marrow  transplanta-
tion. With the B16 mouse melanoma model, Dranoff and col-
leagues  compared  the  effectiveness  of  tumor  cell  vaccines 
transfected  with  various  cytokines  and  adhesion  molecules 
(4). They found that the GM-CSF transduced tumor cell vac-
cine was more effective than any other tumor cell vaccines 
transduced with IL-2, IL-4, IL-5, IL-6, IFN-γ, ICAM-1, CD2, 
and TNFα in the tumor model system. With the purpose to 
enhance  DCs  function,  tumor  cells  were  transduced  with 
GM-CSF or Flt3-ligand, and efficient differentiation and activa-
tion of DCs were acquired with enhanced therapeutic effect 
(31). The enhanced function of DCs resulted in efficient pre-
sentation  of  tumor-associated  antigens  (TAAs)  to  T  cells 
through  cross  presentation,  that  is,  by  indirect  priming 
(Huang et al., 1994). Langerhans cells (LCs), residing DCs in 
epidermis, once receive appropriate stimuli, they engulf anti-
gens and begin their maturation into fully differentiated DCs. 
The activated DCs subsequently migrate with their processed 
antigens to lymph nodes, where they stimulate naïve T cells 
to produce effector cytotoxic T lymphocytes (CTLs). The anti-
gen specific CTLs can leave lymph nodes and move to anti-
gen  invasion  sites  of  body.
  W i t h  t h e  p u r p o s e  o f  d i r e c t  s t i m u l a t i o n  o f  D C s  b y  t u m o r  
cells in situ, Carlo and colleagues prepared P815 mastocyto-
m a  c e l l s  e x p r e s s i n g  G M - C S F  i n  a  m e m b r a n e - b o u n d  f o r m  
(mbGM- CSF) to target TAAs to epidermal LCs (32). High af-
finity  binding  of  mbGM-CSF  to  its  receptors  on  the  LCs  in 
skin  would  yield  a  strong  direct  interaction  with  the 
mbGM-CSF  expressing  tumor  cell  vaccine.  The  transfected 
mbGM-CSF clones stimulated proliferation of syngeneic bone 
marrow  cells,  indicating  that  the  mbGM-CSF  is  biologically 
active.  Growth  of  the  mbGM-CSF  expressing  tumor  clones 
was reduced in syngeneic mice, but not in nude mice. They 
observed that CD8＋ CTLs are involved in the immune res-
ponses. The mice once rejected the mbGM-CSF clones gained 
protective  antitumor  immunity.  Unfortunately,  they  did  not 
analyze the activation of LCs in the analyses of the antitumor 
effect  of  the  mbGM-CSF  expressing  tumor  cells,  and  com-
parative study to the secretory form of GM-CSF has not been 
p e r f o r m e d ,  s o  t h a t  s u p e r i o r i t y  o f  m b G M - C S F  v a c c i n e  c o u l d 
not  be  guaranteed.  They  extended  their  observations  with 
mbGM-CSF  tumor  vaccine  to  the  spontaneously  arisen 
B16F10  mouse  melanoma  tumor  model  (33).  The  B16F10 
cells  are highly metastatic  and  non-immunogenic  compared 
to  the  P815  used  in  previous  study.  Furthermore,  the  B16 
melanoma  model  has  proven  particularly  informative,  be-
cause immunization with irradiated parental cells fails to in-
duce significant levels of protective immunity. With mbGM- 
CSF expressing B16 melanoma vaccine they also recognized 
protective effect and retarded metastasis. In this study they 
found  that  mbGM-CSF  expressing  B16F10  cells  can  induce 
strong systemic immunity; protection and therapeutic effects 
were more effective than analogous vaccines containing only 
secreted  GM-CSF.
    Expression of GM-CSF as a membrane-bound form on the 
highly metastatic Lewis lung carcinoma also led to abrogation 
of their tumorigenicity and metastatic phenotype (34), and at 
the same time induced CTL response that protected syngeneic 
mice against a subsequent challenge with original tumor cells. 
In  leukemia  system,  Arlinghaus  and  colleagues  expressed 
mbGM-CSF,  and  evaluated  the  induction  of  antitumor  im-
m u n i t y  a n d  e f f e c t o r  c e l l s  ( 3 5 ) .  T h e  m b G M - C S F  e x p r e s s i n g  
leukemia cells induced antitumor immunity involving CD8＋ 
T cells. One of critical advantage of the expression of GM-CSF 
in tumor cells is that tedious manipulation to derive sufficient 
numbers of DCs can be avoided for tumor therapy using in 
vitro amplified DCs. However, the supposed maturation and 
differentiation  of  DCs  in  these  antitumor  activities  has  not 
been analyzed systematically. Using macrophage-colony stim-Membrane-bound Form of Cytokine
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Figure 1. The mbCytokines on 
tumor cell vaccines may provide 
costimulatory signal to fulfill the 
requirements for tumor specific CTL 
activation. The tumor cell vaccine 
expressing mbCytokine fulfills the 
two signals required for T cell acti-
vation as in (B), but most tumor 
cells lack proper costimulatory mo-
lecules as in (A). If costimulatory 
molecules, in this case mbCytokine,
are provided, the CTL precursors in
physical contact with tumor cells 
may acquire full signals by direct 
priming, and lead to tumor-specific 
CTL activation selectively.
ulating  factor  (M-CSF)  was  also  investigated  thoroughly. 
Tumor  therapy  using  the  membrane-bound  form  of  M-CSF 
has  been  discussed  in  a  recent  review  (36).
TUMOR THERAPY USING MEMBRANE-BOUND 
FORM OF IL-2
IL-2 is one of the cytokines most widely used for the treat-
ment of patients with cancer. The renal cell carcinoma and 
malignant melanoma was regressed by infusion of high doses 
of  IL-2 (37,38).  The  high  dose of  IL-2  also  induced severe 
adverse events associated with a life-threatening vascular leak 
syndrome mediated by NK cells and neutrophils (39-44). The 
transfer of the IL-2 gene into tumor cells has the advantage 
that IL-2 secreted by the tumor cell itself can induce local im-
mune responses at the tumor growing site. The principle of 
the cytokine gene therapy is based on the findings that tumor 
bearers are often immunocompromized. T lymphocytes from 
the tumor bearers are defective in signaling molecules for T 
cell activation (45,46). The IL-2 gene transduction into tumor 
cells as a tumor cell vaccine was designed to compensate for 
the  defective  cytokines  from  activated  Th  cells  (47-50). 
However, tumor cells engineered to produce cytokines also 
showed unexpected side effects (4,51,52), which may result 
from the paracrine effect of the secreted cytokines stimulating 
bystander  cells  that  are  mostly  non-specific  to  TAAs.
    There  is  a  report  that  membrane-associated  IL-2  is  ex-
pressed  in  certain  population  of  T  cells,  but  its  functional 
meaning was not determined yet (53). A cancer vaccine an-
choring recombinant IL-2 via diphtheria toxin T domain in-
duced  tumor  specific  CTL  activity  (54).  Through  this  ap-
proach they could observe a reduced toxicity of IL-2. As a 
different approach to express membrane-bound form of IL-2 
(mbIL-2),  glycosylphosphatidylinositol  (GPI)-linked  form  of 
IL-2 was expressed as a chimeric form with DAF or CD59, 
GPI-linked  membrane  proteins  (55,56).  The  growth  of  the 
B16 tumor cells expressing GPI-linked IL-2 was inhibited in 
vivo,  but  the  growth  inhibition  was  not  observed  with  the 
tumor  cells  transduced  with  secretory  form  of  IL-2.  The 
GPI-linked protein also has other advantage that the protein 
i s  i n c o r p o r a t e d  i n t o  c e l l  m e m b r a n e  b y  m i x i n g  t u m o r  c e l l s  
with the prepared GPI-linked proteins without involving gene 
transfer and extended in vitro tumor cell culture. One of dis-
advantage of these approaches is that production of IL-2 in 
vivo is no longer happen, so that the benefit of higher im-
munogenicity of live tumor call vaccine should be sacrificed. 
In  our  laboratory,  we  prepared  tumor  vaccines  expressing 
mbIL-2 in other way. IL-2 gene was fused with those of type 
I and II transmembrane proteins (CD4 or TNFα, respectively) 
considering orientation of IL-2 on cell surface (57,58). In this 
approach we postulated that, if tumor cells express IL-2 as 
a costimulatory molecule on tumor cells surface, CTL may get 
two  signals  to  fulfill  activation;  signal  1  from  TAA  pep-
t i d e / M H C  c l a s s  I  c o m p l e x ,  a n d  s i g n a l  2  f r o m  m b I L - 2 .  T h i s  
approach intended selective CTL activation, which is specific 
for TAAs (Fig. 1). The cells will be stimulated through IL-2 
costimulatory signal only when they are in cell-to-cell phys-
ical  contacts through T cell  receptors  (TCR)  and  TAA/MHC 
class I molecules. The expression level of IL-2 as a chimeric 
protein was higher with TNFα than with CD4. In MethA fi-
brosarcoma  model,  the  tumor  cell  clone  expressing  mbIL-2 
was superior to the tumor cells expressing secretory form of Membrane-bound Form of Cytokine
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IL-2 in supporting the growth of IL-2 dependent CTLL-2 cells. 
Moreover, the mbIL-2 expressing MethA clones (L-d positive) 
were better stimulatory for the spleen cells from the 2C TCR 
transgenic mice, which TCR is  responsive to L-d allogeneic 
MHC class I molecule, indicating that the mbIL-2 on tumor 
cells provide signal 2 as costimulatory molecule and the L-d 
molecules  provide  signal  1.  The  tumor  clones  expressing 
mbIL-2  lost  tumorigenicity.  and  the  mice  once  rejected  the 
tumor  clones  showed  resistance  to  re-challenge  with  wild 
type B16 tumor cells (57). This stimulation of antitumor im-
munity was better in tumor clones expressing mbIL-2 than the 
tumor  clone  expressing  secretory  form  of  IL-2.  In  a  mixed 
c e l l  c u l t u r e  o f  s p l e e n  c e l l s  w i t h  i n a c t i v a t e d  t u m o r  c l o n e s  
showed that the mbIL-2 clone was effective in amplification 
of CD8＋ T cells. Furthermore, the mbIL-2 clone produced 
in  B16  melanoma  model  efficiently  inhibited  metastasis  to 
lung by involving CD8＋ T cell activation (58). Another trial 
to accelerate CTL recruitment into tumor growing site, SDF-1 
was transduced into B16 melanoma cells with mbIL-2 (59). 
The additional expression of SDF-1 could enhance the anti-
tumor  immunity  of  mbIL-2  expressing  tumor  cells.
TUMOR THERAPY USING MEMBRANE-BOUND 
FORM OF IL-4
IL-4 is a Th2 cytokine, and mice lacking either IL-4 or IL-4 
receptors fail to develop Th2 cells. IL-4 producing tumor cell 
clones generated by transfection with mouse IL-4 gene caused 
tumor rejection when co-inoculated into nude mice with a va-
riety  of  non-IL-4  producing  tumor  cell  lines.  Rejection  was 
apparently mediated by macrophages and eosinophils which 
could not have been entirely predicted from the previously 
known  functions  of  IL-4.  More  significantly,  IL-4  producing 
tumor cells grew in mice treated with anti-IL-4 antibody, but 
regressed when the antibody therapy was stopped, and local 
IL-4  production  can  cause  regression  of  established  tumors 
(60). IL-4 is a multifunctional cytokine produced by Th2 cells 
and also involved in the generation of CTL. Of several cyto-
kines whose presence affects tumor growth, IL-4 appears to 
be  very  potent.  Tumor  cells  secreting  a  substantial  amount 
of IL-4 are unable to form tumors and induce systemic im-
munity. The IL-4 activated tumor inhibition is a consequence 
of  macrophage  and  eosinophil  infiltration.  Host  T  cells  are 
also involved in the induction and effector phase of IL-4-acti-
vated  tumor  rejection  with  the  antigen  non-specific  cells 
predominating.
    Initial studies have shown that expression of IL-4 in differ-
ent  tumor  types  induced  an  eosinophil-mediated  tumor 
rejection.  Further  studies  demonstrated  that  IL-4  has  pleio-
tropic effects on immune cells of multiple lineages and can 
p a r a d o x i c a l l y  p l a y  a  r o l e  a s  a n  i n d u c e r  o f  t y p e  I  T  c e l l  
immunity. Nave CD8＋ T cells are activated in vitro in the 
presence  of  IL-4  but  not  IL-2  o r  I L - 1 2  a n d  d e v e l o p e d  i n t o  
functional long-term memory cells (61). Moreover, IL-4 from 
CD8＋  T  cells  are  required  for  the  generation  of  tu-
mor-associated CTL (62) and CTL- mediated tumor immunity 
is impaired in IL-4 deficient mice, suggesting tumor immunity 
requires IL-4 in the priming phase for the generation of effec-
tor  cells  (63). 
  P r u d ’homme  and  colleagues  investigated  antitumor  im-
mune  responses  against  human  carcinoembryonic  antigen 
(CEA) with plasmids encoding secretory form of IL-4, IL-12, 
or IFN-γ (64). Intramuscular injection of the IL-12 or IFN-γ 
-encoding plasmid with that of encoding CEA elicited effec-
tive antitumor immune responses to syngeneic CEA-positive 
P815 tumor cells (CEA/P815). In contrast, coinjection of the 
CEA  vector  with  an  IL-4  vector  increased  IgG1  production, 
suppressed the Th1 and CTL activity (high Th2 and low CTL 
activity) and antitumor response. In the following study, they 
intended to enhance adjuvant effects of cytokines and restrict 
the localization of the cytokine to the site of injection by ex-
pressing  membrane-bound  form  of  IL-4  (mbIL-4)  or  mem-
brane-bound form of IL-12 (mbIL-12) (65). Surprisingly, the 
mbIL-4 plasmid was more effective in antitumor immune re-
sponses  than  that  of  mbIL-12  or  secretory  form  of  IL-12. 
These results propose that the function of IL-4 in Th1 immune 
response should be investigated further. We also prepared a 
tumor cell vaccine expressing mbIL-4 in a chimeric form with 
transmembrane  region  of  TNFα (66).  The  mbIL-4  tumor 
clones supported the growth of D10 Th2 cells and CT.4S, an 
IL-4 dependent T cell line, in mixed cell cultures. Moreover, 
the mbIL-4 clone stimulated spleen cells from 2C TCR trans-
genic mice. The tumor clone expressing mbIL-4 failed to form 
tumor, and the mice once rejected the live mbIL-4 clone ac-
quired  systemic  antitumor  immunity.  Though  IL-4  is  ex-
pressed secretory form only naturally, the observed significant 
antitumor effect of the mbIL-4 expressing tumor cell vaccine 
opens the gate of application for other secretory cytokines. 
On the other hand, in virology area, it was reported that in-
corporation of mbCytokines (IL-2, GM-CSF, and IL-4) into in-
fluenza viral vaccines boosted immunogenicity (67), implying 
that  the  mbCytokine  is  applicable  for  therapeutic  develop-Membrane-bound Form of Cytokine
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ment  against  viral  infection,  at  least  to  enveloped  virus.
TUMOR THERAPY USING MEMBRANE-BOUND FORM 
OF IL-12
IL-12 is a cytokine identified as a NK cell stimulatory factor 
and a CTL maturation factor (68,69), and normally released 
by  professional  antigen-presenting  cells.  IL-12  also  induces 
IFN-γ production (70,71), and plays its role as an efficient 
m ol ec u le  fo r t he  in it ia ti on  o f a T h1  re sp on se  (7 2 ). T he re’s 
a report that IL-12 is also expressed as membrane-bound form 
as well as secretory form, but the report has not been con-
firmed conclusively by others yet (73). IL-12 is considered as 
a potent antitumor and antimetastatic cytokine (74). The ad-
ministration  of  recombinant  human  IL-12  is  associated  with 
severe toxicity, and hampers its development as an anticancer 
drug (75-77). Side effects of systemically administered IL-12 
are fever, fatigue, nausea, headache, and sometimes leads to 
death. To avoid the toxicity of IL-12, local delivery methods 
were adopted using plasmid or viral vectors (41,78-80). The 
circulating  cytokine  was  suspected  to  have  some  adverse 
physiological  effects,  such  as  allergy,  immunosuppression, 
systemic mastocytosis, severe hepatic and renal dysfunction 
and cardiotoxicity (65). Tumor cell vaccines prepared by IL- 
12  gene  transfer  into  autologous  cells  also  injected  intra-
dermal or peritumoral sites, and observed reduction of tumor 
size in limited number of patients (78,81). To confine the effec-
tive range of IL-12 and for convenience of practical preparation 
of  tumor  cell  vaccine  expressing  cytokine,  Prud’homme  and 
colleagues tested effectiveness of the DNA vaccines secreting 
IL-12 or expressing mbIL-12 in chimeric form with B7.1 (65). 
The DNA vaccine expressing mbIL-12 also enhanced the anti-
tumor response, but to a slightly lesser extent than secretory 
IL-12 plasmids. The mbIL-12 effect was not much distinct to 
that of secretory form of IL-12 in the model system. Tumor 
cells engineered to express GPI-anchored form of IL-12 also 
induced  antitumor  immunity  (82,83).  Moreover,  the  tumor 
cell vaccine expressing both GPI-linked IL-2 and GPI-linked 
IL-12  showed  synergistic  antitumor  effect  in  subcutaneous 
and  intravenous  tumor  models  (55).  In  our  laboratory,  we 
prepared a tumor vaccine expressing membrane-bound form 
of IL- 12p35 (mbIL-12p35) in a chimeric form with transmem-
brane domain of TNFα. Tumor cells expressing mbIL-12p35 
induced  potent  antitumor  effects  in  MethA  mouse  fi-
brosarcoma model. Tumorigenicity of mbIL-12p35 clone was 
reduced and the mice once rejected the mbIL-12p35 clone ac-
quired systemic antitumor immunity to the wild type tumor 
cells  (unpublished  data).  Analysis  of  effector  cells  involved 
in the antitumor effect of mbIL-4 and mbIL-12 expressing tu-
mor  cell  vaccines  as  representative  Th2  and  Th1  cytokines 
would  provide  information  expla i n i n g  t h e  e f f e c t i v e  C T L  i n-
duction  by  mbIL-4  expressing  tumor  cell  vaccine.
Tumor Therapy Using Membrane-Bound Form 
Of Flt3-ligand, FRACTALKINE, AND IFN-γ
Fms-like tyrosine kinase 3 ligand (Flt3-L) is a cytokine with 
potent costimulatory activity and has a synergistic effect with 
other murine cytokines, especially a growth-stimulatory effect 
on DCs (84) and NK cells (85). Flt3-L is expressed both mem-
brane- bound form and secretory form by alternative splicing 
(10), but functional differentiation of the two types of Flt3-L 
has not been studied yet. The Flt3-L plays an important role 
in the differentiation and maturation of early murine and hu-
man haematopoietic precursor and stem cells. The tumor vac-
cine  expressing  membrane-bound  form  of  Flt3-L  (mbFlt3-L) 
was investigated in murine breast tumor model to investigate 
whether  the  Flt3-L  expression  induces  DC  activation  as 
mbGM-CSF does. This study was intended to take advantage 
of the DC growth-stimulatory effect of Flt3-L (86). In tumor 
cell vaccine trials with both membrane-bound form and secre-
tory  form,  the protective effect  was  comparable  each  other 
(86-88). Furthermore, the effector cells involved in antitumor 
effect was discernable, that is, both the DC and NK cells were 
affected.
    Fractalkine (CX3CL1) is a CX3C chemokine with a CXXXC 
motif at its N-terminus. Fractalkine (FK) is expressed on DCs, 
mast  cells,  and  the  IL-1β or  TNFα-activated  endothelial 
cells, either as a 95 kDa membrane-bound form or as a se-
creted chemokine upon cleavage by ADAM 10 and ADAM17 
proteases  (89).  The  membrane-bound  form  of  FK  (mbFK) 
functions  as  an  effective  adhesion  molecule  by  interacting 
with CX3C chemokine receptor 1 (CX3CR1). Experimentally 
expressed mbFK on tumor cell surface could activate NK cells 
(90). After its release from cell surface, FK also functions as 
a  chemoatttractant  for  monocytes,  NK  cells  and  T  lym-
phocytes. The B16-F0 melanoma cells also express endoge-
nous FK and knock down of FK gene by RNA interference 
reduced  tumor  growth  by  inhibiting  tumor  angiogenesis  in 
mice (91). On the other hand, to take advantage of chemo-
attractive  and  adhesion  functions  of  the  FK,  Cao  and  col-
leagues  prepared  tumor  cells  expressing  secretory  FK  and Membrane-bound Form of Cytokine
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mbFK  by  gene  transfer  into  3LL  lung  carcinoma  cells  (92). 
The 3LL-FK tumor cells induced protective immunity and CTL 
activity. They also observed infiltration of CD4＋ T cells, CD8
＋ T cells, and DCs. Adhesion of DCs by 3LL-FK upregulated 
IL-12  production  by  activated  DCs,  and  production  of  IL-2 
and IFN-γ in 3LL-FK tumor tissues was increased. In mouse 
hapatocellular  carcinoma  model,  the  tumor  cells  expressing 
native form of FK induced similar antitumor activity (93). To 
dissociate  the  function  of  secretory  form  from  the  mem-
brane-bound  form,  Schmid-Antomarch  and  colleagues  com-
pared tumorigenicity of three different transfectants of C26 co-
lon carcinoma cells; natural form, secretory form, and mem-
brane-bound form (94). They found that both secretory and 
membrane-bound form have similar antitumor effect in a sub-
cutaneous  model  of  tumor  implantation,  but  only  secretroy 
form was effective in liver and metastatic lung model of the 
colon cancer. The mbFK even enhanced tumor growth in the 
model  system.  The  induction  of  angiogenesis  and  chemo-
attraction and adhesion functions of FK should be reconciled 
for  successful  tumor  therapy.
  I F N - γ is a potent immunoregulatory molecule secreted by 
NK and T cells. The IFN-γ is detected on the cell surface 
of activated T cells expressing IFN-γ, so that it may function 
as a Th1 marker (15). It abrogated tumor growth by inhibiting 
the proliferation of tumor cells and by activating host immune 
cells including T cells, B cells, macrophages, and NK cells. 
Eisenbach  and  colleagues  expressed  IFN-γ a s  a  m e m -
brane-bound form (mbIFN-γ) in the low immunogenic and 
highly  metastatic  clone  of  3LL  Lewis  lung  carcinoma  and 
found  comparable  effects  to  the  mbGM-CSF  tumor  vaccine 
(34). The responsible effector cells of the antitumor immunity 
by mbIFN-γ producing tumor cell vaccine were not analyzed 
yet.
CONCLUSION
The functional differentiation of the secretory and the mem-
brane-bound  forms  of  cytokine  has  not  been  studied  thor-
oughly yet, but tumor cell vaccines expressing mbCytokines 
showed at least comparable levels of immune stimulatory ef-
fects to secretory cytokine expressing vaccines. As a mecha-
nism of induction of antitumor immunity, indirect priming of 
T cells via professional antigen presenting cells seems to be 
potently  functional  as  seen  with  tumor  vaccines  expressing 
mbGM-CSF and mbFK. The toxicity and side effects of sys-
temically injected recombinant cytokines and secretory cyto-
kines  from  cytokine  gene  transduced  tumor  cell  vaccines 
could be avoided by minimizing incorporation of cytokines 
into circulation, as seen in mbTNFα. In addition, direct pri-
ming of T cells by mbCytokine expressing tumor cell vaccine 
i t s e l f  h a s  b e e n  i n t e n d e d  t o  s e l e c t i v e l y  a c t i v a t e  T A A - s p e c i f i c  
CTL effector cells as in the cases of mbIL-2 or mbIL-4 express-
ing tumor cell vaccines. Expression of chimeric cytokine with 
certain  transmembrane  protein  or  GPI-linkage  signal  se-
quences, and chemical cross-linking of recombinant cytokines 
on  cell  surface  could  be  choices  of  the  tumor  cell  vaccine 
preparation.  Understanding  of  required  costimulatory  mole-
cules for sufficient CTL activation are indispensible for suc-
cessful tumor therapy using CTL-targeted tumor vaccines, be-
cause different origin of tumor cells express different reper-
toire of costimulatory molecules. The effector cells involved 
in the antitumor immunity induction by various mbCytokines 
are  also  waiting  for  further  analysis.
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